HRQOL Data Support First-Line Lenvatinib-Pembrolizumab in Advanced Renal Cell Carcinoma
The median time to definitive deterioration was longer with lenvatinib-pembrolizumab than with sunitinib.
The median time to definitive deterioration was longer with lenvatinib-pembrolizumab than with sunitinib.
Positive surgical margins in patients undergoing robotic partial nephrectomy for renal tumors are associated with adverse oncologic outcomes, a study revealed.
An interim analysis suggests that axitinib given to patients with complex clear cell renal cell carcinoma tumors significantly reduces tumor size and complexity.
Efforts to reduce obesity may cut the prevalence of these urological conditions.
While socioeconomic disparities are evident, survival differences between racial groups persist after RCC diagnosis.
Immune checkpoint inhibitors may be more beneficial than tyrosine kinase inhibitors for patients undergoing cytoreductive nephrectomy for metastatic renal cell carcinoma.
The decision to discontinue was based on data from pre-planned analyses of the phase 3 PIVOT-09 study and the phase 2 PIVOT-10 study.
The TARDIS assay could be used in studies to identify appropriate candidates for discontinuation of immune checkpoint inhibitors.
Investigators in Austria studied overall survival in 914 patients diagnosed with mRCC from July 1985 to September 2020.
Study provides preliminary data on triple therapy for advanced RCC while clinicians await definitive answers from the ongoing phase 3 COSMIC-313 trial.